18 research outputs found

    Impact of Mandated Public Reporting in California on 30-Day readmission following CABG surgery: A Health policy analysis

    No full text
    The 30-day all-cause readmission rate following coronary artery bypass graft (CABG) surgery is considered an important outcome measure for patients because higher rates can be an indicator of low quality and unnecessary health care costs. Our research uses rigorous methods to explore the impact of mandatory public reporting of all-cause readmission rates following CABG surgery in California. We used a hierarchical logistic regression model on 173, 823 CABG patient records. This model standardised outcomes across 10 U.S. states that were not previously comparable due to different CABG definitions and metrics. Additionally, in order to account for the differences in medical practice across different states, we applied a differencein-difference method to estimate the impact of public reporting. Finally, a recycled prediction method was used to estimate the number of averted readmissions following public reporting initiation in California

    Program-Specific Cost-Effectiveness Analysis: Breast Cancer Screening Policies for a Safety-Net Program

    Get PDF
    AbstractBackgroundEvery Woman Counts (EWC), a California breast cancer screening program, faced challenging budget cutbacks and policy choices.MethodsA microsimulation model evaluated costs, outcomes, and cost-effectiveness of EWC program mammography policy options on coverage for digital mammography (which has a higher cost than film mammography but recent legislation allowed reimbursement at the lower film rate); screening eligibility age; and screening frequency. Model inputs were based on analyses of program claims data linked to California Cancer Registry data, Surveillance, Epidemiology, and End Results data, and the Medi-Cal literature. Outcomes included number of procedures, cancers, cancer deaths, costs, and incremental cost per life-year.ResultsProjected model outcomes matched program data closely. With restrictions on the number of clients screened, strategies starting screening at age 40 years were dominated (not cost-effective). This finding was highly robust in sensitivity analyses. Compared with no screening, biennial film mammography for women aged 50 to 64 years was projected to reduce 15-year breast cancer mortality by nearly 7.8% at 18,999peradditionallife−year,annualfilmmammographywas18,999 per additional life-year, annual film mammography was 106,428 per additional life-year, and digital mammography 180,333peradditionallife−year.Thismoreeffective,moreexpensivestrategywasprojectedtoreducebreastcancermortalityby8.6180,333 per additional life-year. This more effective, more expensive strategy was projected to reduce breast cancer mortality by 8.6%. Under equal mammography reimbursement, biennial digital mammography beginning at age 50 years was projected to decrease 15-year breast cancer mortality by 8.6% at an incremental cost per additional life-year of 17,050.ConclusionsFor the EWC program, biennial screening mammography starting at age 50 years was the most cost-effective strategy. The impact of digital mammography on life expectancy was small. Program-specific cost-effectiveness analysis can be completed in a policy-relevant time frame to assist policymakers faced with difficult program choices
    corecore